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Abstract
Introduction: Krabbe disease (KD) or globoid
cell leukodystrophy (GLD) is one of the lysosomal
disorders affecting central and peripheral nervous
systems (CNS and PNS). It is caused by mutations
on the galactocerebrosidase (GALC) gene. Affected
individuals accumulate undegraded substrates and
suffer from neuroinflammation.
Methods: Hematopoietic stem cell transplantation
(HSCT) has been partially successful in treating
patients with KD when accomplished prior to the
onset of symptoms. The success is credited to the ability of the hematopoietic stem cells in providing
some GALC enzyme to the CNS and eradicating potential neuroinflammation. Combination of the
HSCT with some other GALC-providing strategies has shown synergistic effects in the treatment
of the mouse model of this disease.
Results: Here, the possibility of eliminating HSCT in the treatment of human patients and
replacing it with a single therapy that will provide sufficient GALC enzyme to the nervous systems
is suggested. Such treatment, if started during the asymptomatic stage of the disease, not only may
eradicate the enzyme deficiency, but may also keep any neuroinflammation at bay.
Conclusion: Successful treatment of the KD may be possible by restoring consistent and sufficient
GALC expression in CNS and PNS.

Introduction
Krabbe disease (KD) or globoid cell leukodystrophy (GLD)
is a recessive genetic disease caused by the deficiency of a
lysosomal enzyme called galactocerebrosidase (GALC).
KD is a neurodegenerative disorder with progressive
demyelination and oligodendrocytes apoptosis. While
there are late onset and adult forms of this disease, it is
primarily an infantile malady. Affected infants have no
symptoms at birth but begin to develop signs of disease
before about six months of age. Irritability and stiffness
increase with time and the affected, untreated child rarely
lives beyond two years of age.1 There are several animal
models for this disease.2 Twitcher (twi) mouse, the murine
model of the KD has been the subject of many treatment
trials. Bone marrow transplantation (BMT) was the
first treatment strategy applied in twi mice in 19843 and
this resulted in a significant extension of life. Human
patients have been treated by hematopoietic stem cell
transplantation (HSCT)4 and this treatment has become
the standard of care since then. The other treatment

trials practiced in twi mice include neural progenitor/
neural stem cell transplantation,5-7 mesenchymal stem cell
transplantation,8 pharmacological chaperone therapy,9
substrate reduction therapy,10 enzyme replacement
therapy,11,12 antioxidant therapy,13 anti-inflammatory
therapies,14 gene therapy,15-19 and various combinations of
these treatments.20-28 Among these combinatorial therapies,
some demonstrated synergistic effect in improving the
lifespan of the treated mice. At the same time, some
of these treatments resulted in little, if any, increase in
lifespan and some had significant side effects limiting
their use in humans. A closer look at these combinational
therapies applied reveals that the synergistic effect occurs
when both treatments involved in the combination,
either contributed to the enzyme delivery to the CNS2025
or played a role in the substrate reduction approach.26
These findings highlight the importance of delivering
sufficient GALC to the nervous system or reducing the
undegraded materials. Such a crucial role of GALC has
been demonstrated recently in twi mice29,30 and the canine
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model of GLD.31 Based on the results of the different
combinational therapies, outcomes of the recent studies,
and serious side effects of myeloablation required for cell
transplantation, the aim of this article is to hypothesize
that BMT/HSCT can entirely be eliminated from GLD
treatment without being excessively concerned about
the neuroinflammation or other secondary hits, such as
psychosine toxicity. This, of course, requires supplying
adequate GALC activity by another approach, such as
gene therapy, in a timely manner.
Fig. 1. Role of BM cells in providing GALC. Cutting viral dose in half
or using BM cells from heterozygote mouse in a combination of BMT and
gene therapy treatments results in a similar reduction in lifespan of the
treated mice.30

Role of BMT in combination with any enzyme supplying
methodology
Combination of BMT and gene therapy or any other type
of enzyme delivery system to the CNS, has shown strong
synergistic effect reported by us and other colleagues.19,20
The mechanism of such synergistic effect has also been
the subject of multiple studies20,21 with no clear conclusion.
In previous publications, we have emphasized the antiinflammatory role of BMT/HSCT in the treatment of the twi
mice or human patients.14-19 In our latest publications,29,30
we have also acknowledged the GALC delivery capacity
and anti-inflammatory properties of BM cells. However,
here, we are highlighting the GALC delivery role of BMT
over its anti-inflammatory function. The GALC delivery
capability of BMT combined with another GALC source
appear to exhibit either additive or synergistic effects
in these experiments without involvement of any antiinflammatory action from BM cells. The logic behind such
hypotheses is that there is no plausible neuroinflammation
at the early stage of the disease. In other words, the antiinflammation property of the BM cells is still there but not
in use because of the timing. As we have shown previously,
a) treatment of the twi mice with anti-inflammatory drugs
failed to demonstrate any positive outcome in treating
these mice at a young age,14 b) decreasing viral dose in
half with regular BMT, compared to injecting full viral
dose along with BMT using BM cells from heterozygote
mice resulted in similar reduced lifespan (Fig. 1).29 This
confirms the pivotal role of GALC activity provided by
BMT and gene therapy. Another point worth mentioning
here, is that AAVrh10, and potentially some other AAV
serotypes, is/are capable of in vivo and in vitro transducing
the BM cells.30 This is an additional reason for eliminating
BMT in combination with gene therapy, as we are hitting
two targets when using high dose gene therapy alone:
delivering enzyme to the nervous system directly and via
the transduced BM cells indirectly.

there is higher GALC activity in the CNS, meaning that a
higher number of viral particles have reached the brain,
resulting in a much better outcome. While the level of
the supplied enzyme to the nervous systems is pivotal for
successful therapy, the goal should be supplying enough
GALC activity to the nervous system not overwhelming it.
Treatment time: An encouraging point about this
disease is that both human patients and animal models
enjoy an asymptomatic period after birth. All human
patients and animal models of GLD are normal at birth
until a certain time, depending on the species. No
pathological abnormalities, such as CNS inflammation,
nor increased psychosine, seem to be at an alarming
level during these asymptomatic periods. This timeframe
provides a sufficient window of opportunity to initiate
treatments in a preventive manner. To take advantage
of this asymptomatic period, the at-risk children should
be determined as soon as possible. Such identification
is being done by newborn screening (NBS) programs in
several states of the USA.33 In the case of the twi mice,
the symptoms appear at postnatal day 21 (PND21).
Therefore, the safe period for any intervention will be
from PND0 until about PND18. For instance, we have
shown successful results when treatment was completed
between PND8 to PND18. It’s reasonably assumed that
for any treatment, earlier is better. This approach may
prevent pathological changes in the CNS and PNS prior to
becoming clinically intractable and irreversible. However,
when there is a wide window of treatment opportunity,
determining the optimal window of opportunity may be
preferable to avoid potential complications. For instance,
treatment started in utero, may be possible but could
result in unforeseen complications.

Importance of the enzyme level in the CNS and time of
the treatment
Enzyme level: As the ability of the current AAV serotypes
in crossing the blood brain barrier (BBB) is limited,32 the
level of GALC delivered to the CNS will directly depend
on the number of the viral particles reaching the brain.
With high viral dose, as shown by us30 and Bradbury et al,31

Treatment options
While the goal is to find a safe and efficacious therapy for
human patients, for the sake of simplicity and immediate
evaluation of the potential outcomes, the treatment
options are largely discussed on twi mice. Furthermore,
as the most promising way of supplying GALC enzyme to
the CNS seems to be under the umbrellas of gene therapy
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and gene editing technologies, here, the discussion will be
limited to the gene therapy options. While gene therapy
has great potential for the treatment of neurological
diseases, the biggest hurdle has been the transfer of the
viral vectors to the CNS. The BBB blocks delivery of most
drugs to the brain. Currently, several newly developed
AAV serotypes such as AAV9 and AAVrh10 and their
variants such as AAV-PHP.B and AAV-PHP.eB can cross
the BBB of mice though with low efficiency.32 Most of the
injected viral vectors get trapped in peripheral organs such
as the heart, skeletal muscles, and liver. Only a fraction
of these viral particles succeeds in crossing the BBB and
reaching the brain tissues. Therefore, the ideal solution for
the current hurdle will be developing viral vectors with
a higher capacity of crossing the BBB. However, in the
absence of such viral vectors, alternative potentially useful
approaches can be considered:
1) Increasing the viral load: We have recently
demonstrated the enhancing effect of such an
increase.29,30 Our regular dose of intravenous injection
of AAVrh10-mGALC in twi mice was 4×1013 gc/kg of
body weight. With this injection dose without BMT,
the lifespan of the twi mice was increased from about
40 days to 72 days. A four-fold and ten-fold increase
of this injection dose (1.6×1014 gc/kg and 4×1014 gc/
kg), raised the median lifespan of the twi mice to 180
days and 280 days respectively without any apparent
toxicity. The 4×1014 gc/kg dose may not be the upper
limit that could be administered. However, at some
point, toxicity may become a factor to be considered.
2) Double injection: If increasing viral dose over 4×1014
gc/kg is not tolerated, because of immune system
constraints or risk of neoplastic changed in the
liver, the same dose can be injected in two different
intervals (e.g., PND10 and 15 in twi mice). Of
course, the second injection needs to be done in a
short interval before any potential immune reactions
develop after the first injection.
3) Combination of two viral serotypes: As discussed
above, currently, AAVrh10 and AAV9 are the two
available serotypes that can cross the BBB more
efficiently than the other serotypes. However, the
mechanisms utilized by these viruses to enter the
CNS are unknown.32 If injected within a safe time
frame (for instance, PND10 and 15 in twi mice), it
may result in a better outcome. The advantage of
this method, relative to the multiple injections of
one serotype, is that different serotypes may utilize
alternating or distinct pathways in crossing the BBB
and, therefore, using different serotypes will increase
the overall delivery rate to the CNS while decreasing
any potential of immune response.
4) Mobilizing the innate BM cells before viral injection:
AAVrh10 is capable of in vivo transducing the BM
cells.30 It has also been shown that mobilizing the
BM cells into the bloodstream significantly increases

the transduction rate after adenovirus injection.34
This could happen for the AAV viral vectors too.
The transduced cells return to the bone marrow
compartment for engraftment.34
5) Temporarily opening the BBB prior to viral injection:
It has been known that the BBB can be temporarily
opened for drug delivery. Focused ultrasound strategy
is one such method that can transiently increase
BBB permeability for certain impenetrable drugs.35
Mannitol mediated osmotic destruction of the BBB
is another strategy to assist viral vectors entering the
CNS. Such approach has been shown effective in
treatment of type IIIB mucopolysaccharide disease.36
6) Generating an engineered AAV-GALC construct:
Recently, several studies have demonstrated that
molecular engineering of a transgene significantly
enhances the ability of the viral construct to cross the
BBB. Addition of the signal peptide from the highly
secreted iduronate-2-sulfatase and the BBB-binding
domain from the Apolipoprotein B (ApoB-BD) to the
viral construct have been reported in mouse model
of mucopolysaccharidoses type IIIA to increase the
expression of the transgene and facilitate crossing
the BBB.37 Similar improvement in crossing BBB has
also been shown in twi mice.38,39 Such methodologies
can be combined with higher viral dose injection to
improve the outcome.
7) Developing a carrier-mediated method of crossing the
BBB: Several carrier-mediated strategies have been
developed to assist the viral particles in crossing the
BBB. Some of these practical strategies have been
summarized by Bellettato and Scarpa.40 In receptormediated transcytosis approaches, viral vectors
interact directly with extracellular receptors of the
capillary endothelial cells to facilitate crossing the
BBB.32
Discussion
The initial idea of BMT in treatment of the mouse model
of KD, was based on the ability of the BM cells to secrete
the missing enzyme that can be taken up by the enzymedeficient cells via cross-correction.3 While the in vivo
“cross-correction” of GALC has been recently questioned
by Weinstock et al,41 independent of the mechanism of
BMT, as shown by us16-19 and others,42 delivering sufficient
GALC to the CNS and PNS via any methodology is the
key for the effective treatment of KD. Such delivery should
be accomplished at the pre-symptomatic stage to prevent
accumulation of the toxic materials. Currently, HSCT
is the “standard of care” treatment for human patients.
However, newer technologies of delivering GALC to the
nervous system have emerged and their application alone
or in combination with BMT in animal models of KD
have been the subject of many studies. These technologies,
including enzyme replacement therapy, neural-stem cell
transplantation, as well as gene therapy, have improved
BioImpacts, 2022, 12(1), 3-7
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Review Highlights
What is the current knowledge?
√ BMT/HSCT has the capacity of providing some GALC
activity to the CNS.
√ The success of BMT/HSCT was mostly credited to the
ability of the BM cells in eradicating neuroinflammation in
the CNS.
What is new here?
√ The positive role of BMT/HSCT relies on its ability to
provide substantial amount of GALC enzyme to the CNS and
PNS.
√ AAVrh10 is capable of in vivo transduction of bone marrow
cells.
√ BMT/HSCT may be eliminated completely by supplying
sufficient GALC activity to the CNS and PNS via any other
methodologies.

our understanding of the disease and helped to better
recognize the unmet needs for treating this disease.
Combination of these new methods with BMT in animal
models, revealed an interesting synergistic effect on the
lifespan of the treated mice. These very encouraging results
in animal models paved the way for the current clinical
trial in humans (Forge Biologics, see NCT04693598).
However, with such promising combinational therapy
on human patients, the study on the animal models did
not stop. While acknowledging the anti-inflammatory
property of the HSCT, its synergistic effect with other
treatments highlights the importance of supplying extra
GALC enzyme to the nervous system. Considering the
side effects of the BMT/HSCT, such as infertility and
overall abnormal growth, replacing it with other enzymeproviding treatment options may be preferable. Two
independent studies in two different animal models of
KD30,31 have already demonstrated that increasing GALC
expression in the CNS and PNS via gene therapy, can
substitute the GALC delivery share of the BMT and,
therefore, have validated that BMT can completely be
eliminated from the combinational therapies.
Conclusion
According to the current state of the knowledge and
what was discussed above, it appears that exogenous
BMT in animal models of KD or HSCT in human
patients may soon be obsolete. Restoring consistent and
sufficient GALC expression in the CNS and PNS via any
methodology may be a safe and efficacious treatment for
KD. The subject remains for further validation.
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Author’s Note
My interest in Krabbe disease began in 1987 when I joined Professor
David A. Wenger’s laboratory at Thomas Jefferson University,
Philadelphia. This was soon after Dr. Wenger had established the
Diagnostic and Research Laboratories for lysosomal storage diseases.
While we initiated working on several lysosomal disorders, our research
was mostly focused on Krabbe disease. The breakthrough was when
Dr. Yue Qun Chen joined our research team. With his pivotal efforts,
we purified and characterized GALC, the missing enzyme in Krabbe
disease. This opened the way for the cloning of cDNA of this protein for
human and several animal models of this disease. Since then, beside the
continuous efforts toward disease-related studies such as characterization
of the gene and mutational analysis, the aim was focused on exploring
the treatment options for this devastating disease. In this brief article,
shortly after my retirement, I wanted to share my experiences and views
and provide hypothesis toward potential enhancements of the current
clinical trial in humans.
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